The results from a DCVax immunotherapy trial show increased lifespan for  patients diagnosed with glioblastoma. Glioblastoma, an aggressive form of brain cancer, is difficult to treat and patients are usually given only around 14 months to live. Could this new treatment make a significant difference to patients and families affected by this aggressive brain cancer? Or should we be cautious of the optimistic results? To discuss this further, Dr Kelly McKelvey from the Matt Callander Beanie for Brain Cancer HMRI Fellow and researcher at the University of Sydney Northern Clinical School; will be joining us soon.